JMP Securities Increases LeMaitre Vascular (NASDAQ:LMAT) Price Target to $77.00

LeMaitre Vascular (NASDAQ:LMAT) had its target price raised by research analysts at JMP Securities from $72.00 to $77.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “market outperform” rating on the medical instruments supplier’s stock. JMP Securities’ price objective suggests a potential upside of 3.75% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. KeyCorp began coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their target price for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, Barrington Research upped their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a report on Friday. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average price target of $73.83.

LeMaitre Vascular Trading Up 11.2 %

LMAT stock traded up $7.45 during midday trading on Friday, hitting $74.22. The stock had a trading volume of 329,984 shares, compared to its average volume of 110,751. The firm has a market cap of $1.67 billion, a P/E ratio of 49.15, a price-to-earnings-growth ratio of 3.20 and a beta of 0.88. The business has a fifty day moving average price of $65.93 and a two-hundred day moving average price of $58.78. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.75% and a net margin of 16.99%. The firm had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. During the same period last year, the company posted $0.27 EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. On average, equities analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares in the company, valued at approximately $358,357.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares in the company, valued at $358,357.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the transaction, the chief financial officer now directly owns 6,452 shares in the company, valued at $450,091.52. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock worth $7,873,749 in the last quarter. Insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors have recently modified their holdings of the business. Conestoga Capital Advisors LLC lifted its holdings in LeMaitre Vascular by 0.3% during the first quarter. Conestoga Capital Advisors LLC now owns 1,932,917 shares of the medical instruments supplier’s stock worth $128,268,000 after acquiring an additional 4,946 shares during the period. Vanguard Group Inc. raised its stake in shares of LeMaitre Vascular by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after purchasing an additional 38,303 shares during the period. Copeland Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 2.3% in the 4th quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock worth $71,515,000 after buying an additional 28,720 shares during the last quarter. Ranger Investment Management L.P. grew its position in LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after buying an additional 13,681 shares during the period. Finally, Congress Asset Management Co. MA increased its holdings in LeMaitre Vascular by 12.0% during the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after buying an additional 71,411 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.